Olli Aitio

Olli Aitio

Auto-generated profile, based on publicly available information

Olli Aitio

Glykos Finland Oy, Helsinki, Finland. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
TSTero Satomaa
Tero Satomaa
HPHenna Pynnönen
Henna Pynnönen
OAOlli Aitio
Olli Aitio
JHJukka O. Hiltunen
Jukka O. Hiltunen
VPVirve Pitkänen
Virve Pitkänen
JSJuhani Saarinen
Juhani Saarinen
CD33 (Siglec-3) is a cell surface receptor expressed in approximately 90% of acute myeloid leukemia (AML) blasts, making it an attractive target for therapy of AML. Although previous CD33-targeting antibody–drug conjugates (ADC) like gemtuzumab ozogamicin (GO, Mylotarg) have shown efficacy in AML treatment, they have suffered from toxicity and narrow therapeutic window. This study aimed to develop a novelADCwith improved tolerability and a wider therapeutic window. GLK-33 consists of the anti-CD33 antibody lintuzumab and eight mavg-MMAU auristatin linkerpayloads per antibody. The experimental methods included testing in cell cultures, patient-derived samples, mouse xenograft models, and rat toxicology studies. GLK-33 exhibited remarkable efficacy in reducing cell viability within CD33-positive leukemia cell lines and primary AML samples. Notably, GLK-33 demonstrated antitumor activity at single dose as low as 300 mg/kg in mice, while maintaining tolerability at single dose of 20 to 30 mg/kg in rats. In contrast with both GO and lintuzumab vedotin, GLK-33 exhibited a wide therapeutic window and activity against multidrug-resistant cells. The development of GLK-33 addresses the limitations of previous ADCs, offering a wider therapeutic window, improved tolerability, and activity against drug-resistant leukemia cells. These findings encourage further exploration of GLK-33 in AML through clinical trials.

7 February 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
SGShalom D. Goldberg
Shalom D. Goldberg
TSTero Satomaa
Tero Satomaa
OAOlulanu Aina
Olulanu Aina
OAOlli Aitio
Olli Aitio
KBKrista Burke
Krista Burke
JSJuhani Saarinen
Juhani Saarinen
Antibody–drug conjugates (ADC) have shown impressive clinical activity with approval of many agents in hematologic and solid tumors. However, challenges remain with both efficacy and safety of ADCs. This study describes novel trastuzumab–auristatin conjugates with the hydrophilic monomethylauristatin E (MMAE) prodrug MMAU, and optimization of a glycopeptide linker leading to a wider therapeutic window. Trastuzumab was conjugated with auristatin payloads via a series of linkers using a stabilized maleimide handle. The ADCs were characterized in vitro and their relative in vivo antitumor efficacies were assessed in HER2+ xenograft models. Relative linker stabilities and the mechanism of linker cleavage were studied using in vitro assays. Toxicity and toxicokinetics of the best performing ADC were evaluated in cynomolgus monkey (cyno). The trastuzumab–MMAU ADC with stabilized glycopeptide linker showed maleimide stabilization and higher resistance to cleavage by serum and lysosomal enzymes compared with a valine–citrulline conjugated trastuzumab ADC (trastuzumab–vc-MMAE). A single dose of 1 or 2 mg/kg of trastuzumab–MMAU at drug-to-antibody ratios (DAR) of eight and four respectively resulted in xenograft tumor growth inhibition, with superior efficacy to trastuzumab–vc-MMAE. Trastuzumab–MMAUDAR4 was tolerated at doses up to 12 mg/kg in cyno, which represents 2- to 4-fold higher dose than that observed with vedotin ADCs, and had increased terminal half-life and exposure. The optimized trastuzumab–MMAU ADC showed potent antitumor activity and was well tolerated with excellent pharmacokinetics in nonhuman primates, leading to a superior preclinical therapeutic window. The data support potential utility of trastuzumab–MMAU for treatment of HER2+ tumors.



17 June 2026
Verified
Other
Open access
SGShalom D. Goldberg
Shalom D. Goldberg
TSTero Satomaa
Tero Satomaa
OAOlulanu Aina
Olulanu Aina
OAOlli Aitio
Olli Aitio
KBKrista Burke
Krista Burke
JSJuhani Saarinen
Juhani Saarinen
Lysosomal degradation of T-mcvc-MMAE DAR4 and T-mavg-MMAU DAR8.

17 June 2026
Verified
Other
Open access
SGShalom D. Goldberg
Shalom D. Goldberg
TSTero Satomaa
Tero Satomaa
OAOlulanu Aina
Olulanu Aina
OAOlli Aitio
Olli Aitio
KBKrista Burke
Krista Burke
JSJuhani Saarinen
Juhani Saarinen
Comparison of published toxicokinetic parameters of approved vedotin ADCs with T-mavg-MMAU DAR4.